Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPLENEVAC-2: Revaccination With PPS23 Boosted or Not by PCV13 in Splenectomised Patients
NCT03873727Phase 2Completed
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Aug 2019
- Primary completion
- May 2022
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in pneumococcal infection comparing Prevenar13/ Pneumovax with Placebo / Pneumovax (2 arms). Primary endpoint: Proportion of patients responding to a minimum of 5 of the 9 serotypes analysed at 13 months. Started Aug 2019; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03873727.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03873727.